Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
European Journal of Cancer · 2023
DOI: 10.1016/j.ejca.2023.113245 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Hans Gelderblom und 28 weiteren Autor:innen. Beteiligte Einrichtung: Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FDA HHS, NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leiden University Medical Center, Leiden, the Netherlands.
- Royal Marsden Hospital and Institute of Cancer Research, London, UK.
- Centre Léon Bérard and University Claude Bernard Lyon 1, Lyon, France.
- Dana-Farber Cancer Institute, Boston, MA, USA.
- Fox Chase Cancer Center, Philadelphia, PA, USA.
- Department of Medical Oncology, Alfred Health and School of Public Health, Monash University, Melbourne, Australia.
Förderung
- FDA HHS
- NCI NIH HHS
Zitieren
APA
Gelderblom, H., Jones, R. L., Blay, J. Y., George, S., von Mehren, M., Zalcberg, J. R., Kang, Y. K., Razak, A. A., Trent, J., Attia, S., Le Cesne, A., Siontis, B. L., Goldstein, D., Boye, K., Sanchez, C., Steeghs, N., Rutkowski, P., Druta, M., Serrano, C., …, & INTRIGUE investigators (2023). Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.113245
Vancouver
Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, et al. Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.113245
BibTeX
@article{Gelderblom2023,
author = {Gelderblom, Hans and Jones, Robin L and Blay, Jean-Yves and George, Suzanne and von Mehren, Margaret and Zalcberg, John R and Kang, Yoon-Koo and Razak, Albiruni Abdul and Trent, Jonathan and Attia, Steven and Le Cesne, Axel and Siontis, Brittany L and Goldstein, David and Boye, Kjetil and Sanchez, Cesar and Steeghs, Neeltje and Rutkowski, Piotr and Druta, Mihaela and Serrano, César and Somaiah, Neeta and Chi, Ping and Harrow, Brooke and Becker, Claus and Reichmann, William and Sherman, Matthew L and Ruiz-Soto, Rodrigo and Heinrich, Michael C and Bauer, Sebastian and INTRIGUE investigators, INTRIGUE investigators},
title = {Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study},
journal = {European Journal of Cancer},
year = {2023},
doi = {10.1016/j.ejca.2023.113245}
}
EUVIMED